These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. Morris V; Rao X; Pickering C; Foo WC; Rashid A; Eterovic K; Kim T; Chen K; Wang J; Shaw K; Eng C Mol Cancer Res; 2017 Nov; 15(11):1542-1550. PubMed ID: 28784613 [TBL] [Abstract][Full Text] [Related]
5. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial. Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. De Dosso S; Martin V; Zanellato E; Frattini M; Saletti P Tumori; 2010; 96(4):627-8. PubMed ID: 20968146 [TBL] [Abstract][Full Text] [Related]
8. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018 [TBL] [Abstract][Full Text] [Related]
9. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102 [TBL] [Abstract][Full Text] [Related]
10. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD Oncology; 2017; 92(4):190-196. PubMed ID: 28152526 [TBL] [Abstract][Full Text] [Related]
12. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Mao C; Yang ZY; Hu XF; Chen Q; Tang JL Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088 [TBL] [Abstract][Full Text] [Related]
14. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study. Truelsen CG; Serup-Hansen E; Storm KS; Havelund BM; Kronborg CS; Spindler KG Cancer Med; 2021 May; 10(10):3224-3230. PubMed ID: 33960701 [TBL] [Abstract][Full Text] [Related]
15. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692 [TBL] [Abstract][Full Text] [Related]
16. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal. Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335 [TBL] [Abstract][Full Text] [Related]
17. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995 [TBL] [Abstract][Full Text] [Related]
18. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. Lonardi S; Prete AA; Morano F; Messina M; Formica V; Corsi DC; Orciuolo C; Frassineti GL; Zampino MG; Casagrande M; Masi G; Ronzoni M; Scartozzi M; Buonadonna A; Mosconi S; Ratti M; Sartore-Bianchi A; Tamburini E; Prisciandaro M; Bergamo F; Spada M; Corallo S; Vettore V; Loupakis F; Fassan M; Del Bianco P; Zagonel V; Pietrantonio F J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815354 [TBL] [Abstract][Full Text] [Related]
20. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]